• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为欧洲初级保健从业者开展非酒精性脂肪性肝病继续医学教育项目并予以实施。

Development and implementation of a continuing medical education program on non-alcoholic fatty liver disease for primary care practitioners in Europe.

作者信息

Papadakis Sophia, Anastasaki Marilena, Gergianaki Irini, Koek Ger, Mendive Juan, Anastasiou Foteini, Heyens Leen, Garcia-Retortillo Montserrat, Muris Jean, Lionis Christos

机构信息

Clinic of Social and Family Medicine, School of Medicine, University of Crete, Crete, Greece.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands.

出版信息

Front Med (Lausanne). 2023 Mar 23;10:1034626. doi: 10.3389/fmed.2023.1034626. eCollection 2023.

DOI:10.3389/fmed.2023.1034626
PMID:37035308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10077524/
Abstract

BACKGROUND

Primary care has a crucial role to play in the prevention, early detection, referral, and risk factor management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NAFLD/NASH). In 2021, a team of European collaborators developed a continuing medical education (CME) program on NAFLD/NASH that consolidates evidence and clinical best practices tailored to the primary care setting. This article reports on the methodology used to design and develop the CME and the results of a feasibility study.

METHODS

An expert advisory group representing both European specialists and general practitioners supported the design of the CME to be implemented in three European settings (Greece, Spain, and Netherlands). The CME features four training modules and problem-based learning using clinical case studies. The CME was tested regarding feasibility and acceptability among a sample of primary care providers (PCPs) in Greece ( = 28) with measurements occurring before, immediately after, and 1 month following the training. Outcome measures included satisfaction with the CME, changes in PCPs' knowledge, attitudes, confidence, and self-reported clinical practices related to NAFLD/NASH.

RESULTS

The CME is available as an open-access e-learning course on the European Society for Primary Care Gastroenterology education platform in English, Greek, Spanish, and Dutch. The feasibility study documented high levels of satisfaction, with 96% of PCPs reporting they were extremely or very satisfied with the overall training. Statistically significant increases in PCPs' confidence in NAFLD/NASH-related clinical practices were documented between the pre- and post-assessments. At the follow-up, 62% of GPs reported that the CME had changed their clinical practices related to NAFLD/NASH to a great extent.

CONCLUSION

This CME intervention developed by experts and tailored to PCPs in European settings may serve as an asset for increasing knowledge, confidence, and practice behaviors related to NAFLD/NASH.

摘要

背景

初级保健在非酒精性脂肪性肝病和非酒精性脂肪性肝炎(NAFLD/NASH)的预防、早期检测、转诊及危险因素管理中发挥着关键作用。2021年,一组欧洲合作者开发了一项关于NAFLD/NASH的继续医学教育(CME)项目,该项目整合了针对初级保健环境的证据和临床最佳实践。本文报告了用于设计和开发该CME的方法以及一项可行性研究的结果。

方法

一个由欧洲专家和全科医生组成的专家咨询小组支持了将在三个欧洲地区(希腊、西班牙和荷兰)实施的CME的设计。该CME有四个培训模块,并采用基于临床案例研究的问题式学习。在希腊的28名初级保健提供者(PCP)样本中对该CME的可行性和可接受性进行了测试,在培训前、培训后立即以及培训后1个月进行测量。结果指标包括对CME的满意度、PCP在NAFLD/NASH相关知识、态度、信心以及自我报告的临床实践方面的变化。

结果

该CME作为一门开放获取的电子学习课程,可在欧洲初级保健胃肠病学学会教育平台上以英语、希腊语、西班牙语和荷兰语获取。可行性研究记录了高水平的满意度,96%的PCP报告他们对整体培训极其或非常满意。在评估前和评估后之间,记录到PCP在NAFLD/NASH相关临床实践方面的信心有统计学意义的增加。在随访中,62%的全科医生报告该CME在很大程度上改变了他们与NAFLD/NASH相关的临床实践。

结论

由专家开发并针对欧洲环境中的PCP量身定制的这种CME干预措施,可能有助于增加与NAFLD/NASH相关的知识、信心和实践行为。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed0c/10077524/485412cde8ac/fmed-10-1034626-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed0c/10077524/0fb3158d9f7d/fmed-10-1034626-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed0c/10077524/cdb234a8f412/fmed-10-1034626-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed0c/10077524/485412cde8ac/fmed-10-1034626-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed0c/10077524/0fb3158d9f7d/fmed-10-1034626-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed0c/10077524/cdb234a8f412/fmed-10-1034626-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed0c/10077524/485412cde8ac/fmed-10-1034626-g003.jpg

相似文献

1
Development and implementation of a continuing medical education program on non-alcoholic fatty liver disease for primary care practitioners in Europe.为欧洲初级保健从业者开展非酒精性脂肪性肝病继续医学教育项目并予以实施。
Front Med (Lausanne). 2023 Mar 23;10:1034626. doi: 10.3389/fmed.2023.1034626. eCollection 2023.
2
Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?非酒精性脂肪性肝炎的认知与治疗指南:医生们告诉了我们什么?
World J Hepatol. 2021 Feb 27;13(2):233-241. doi: 10.4254/wjh.v13.i2.233.
3
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.一项关于欧洲对非酒精性脂肪性肝病公共卫生应对措施的横断面研究。
J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10.
4
A Canadian survey on knowledge of non-alcoholic fatty liver disease among physicians.一项关于加拿大医生对非酒精性脂肪性肝病认知情况的调查。
Can Liver J. 2021 Apr 29;4(2):82-92. doi: 10.3138/canlivj-2020-0033. eCollection 2021 Spring.
5
Differences in NAFLD/NASH Management by Provider Specialty: Opportunities for Optimizing Multidisciplinary Care.不同医疗服务专业人员对非酒精性脂肪性肝病/非酒精性脂肪性肝炎的管理差异:优化多学科护理的机会
J Multidiscip Healthc. 2022 Jul 19;15:1533-1545. doi: 10.2147/JMDH.S367607. eCollection 2022.
6
Primary care practitioners survey of non-alcoholic fatty liver disease.基层医疗从业者对非酒精性脂肪性肝病的调查。
Ann Hepatol. 2013 Sep-Oct;12(5):758-65.
7
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.欧洲和美国非酒精性脂肪性肝炎的成本:GAIN研究。
JHEP Rep. 2020 Jul 15;2(5):100142. doi: 10.1016/j.jhepr.2020.100142. eCollection 2020 Oct.
8
European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?欧洲“非酒精性脂肪性肝病准备指数”——欧洲是否做好应对脂肪肝疾病挑战的准备?
JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.
9
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.非酒精性脂肪性肝病全谱的代谢特征
JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.
10
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.基层医疗和糖尿病诊疗中,非酒精性脂肪性肝病高危患者的临床评估。
Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.

引用本文的文献

1
Cross-sectional Study of Resident Physician Knowledge and Perceptions Regarding MASLD in Canada.加拿大住院医师关于代谢功能障碍相关脂肪性肝病(MASLD)的知识与认知的横断面研究
Can Liver J. 2025 Feb 25;8(1):8-17. doi: 10.3138/canlivj-2024-0009. eCollection 2025 Feb.
2
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos.心力衰竭中的心血管、肾脏、肝脏及代谢相互作用:打破壁垒
Circ Res. 2025 May 23;136(11):1170-1207. doi: 10.1161/CIRCRESAHA.125.325602. Epub 2025 May 22.
3
A Survey Assessing Nonalcoholic Fatty Liver Disease Knowledge Among Hepatologists and Non-Hepatologists in China.

本文引用的文献

1
A Canadian survey on knowledge of non-alcoholic fatty liver disease among physicians.一项关于加拿大医生对非酒精性脂肪性肝病认知情况的调查。
Can Liver J. 2021 Apr 29;4(2):82-92. doi: 10.3138/canlivj-2020-0033. eCollection 2021 Spring.
2
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.欧洲肝脏研究学会-《柳叶刀》肝脏委员会:保护下一代欧洲人免受肝脏疾病并发症和过早死亡的影响。
Lancet. 2022 Jan 1;399(10319):61-116. doi: 10.1016/S0140-6736(21)01701-3. Epub 2021 Dec 2.
3
Non-alcoholic fatty liver disease: A patient guideline.
一项评估中国肝病专家和非肝病专家对非酒精性脂肪性肝病知识掌握情况的调查。
JGH Open. 2024 Dec 10;8(12):e70054. doi: 10.1002/jgh3.70054. eCollection 2024 Dec.
4
Development and pilot evaluation of an evidence-based algorithm for MASLD (formerly NAFLD) management in primary care in Europe.欧洲基层医疗中基于证据的成人非酒精性脂肪性肝病(原非酒精性脂肪性肝病)管理算法的开发与试点评估。
Front Med (Lausanne). 2024 Nov 21;11:1383112. doi: 10.3389/fmed.2024.1383112. eCollection 2024.
5
Practice Recommendations for the Management of MASLD in Primary Care: Consensus Results.基层医疗中MAFLD管理的实践建议:共识结果
Diseases. 2024 Aug 10;12(8):180. doi: 10.3390/diseases12080180.
6
Barriers to care linkage and educational impact on unnecessary MASLD referrals.护理联系的障碍以及对不必要的代谢功能障碍相关脂肪性肝病(MASLD)转诊的教育影响。
Front Med (Lausanne). 2024 Jul 25;11:1407389. doi: 10.3389/fmed.2024.1407389. eCollection 2024.
非酒精性脂肪性肝病:患者指南。
JHEP Rep. 2021 Sep 17;3(5):100322. doi: 10.1016/j.jhepr.2021.100322. eCollection 2021 Oct.
4
Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis.欧洲非酒精性脂肪性肝病的流行病学:一项系统评价和荟萃分析。
Ann Gastroenterol. 2021;34(3):404-414. doi: 10.20524/aog.2021.0604. Epub 2021 Feb 26.
5
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.非酒精性脂肪性肝病、胰岛素抵抗、代谢综合征及其与血管风险的关系。
Metabolism. 2021 Jun;119:154770. doi: 10.1016/j.metabol.2021.154770. Epub 2021 Apr 14.
6
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.2型糖尿病、非酒精性脂肪性肝病与心血管风险之间的关系
Curr Diab Rep. 2021 Mar 19;21(5):15. doi: 10.1007/s11892-021-01383-7.
7
Fatty liver, cardiometabolic disease and mortality.脂肪肝、代谢相关心血管疾病与死亡
Curr Opin Lipidol. 2020 Feb;31(1):27-31. doi: 10.1097/MOL.0000000000000652.
8
Obesity and nonalcoholic fatty liver disease: current perspectives.肥胖与非酒精性脂肪性肝病:当前观点
Diabetes Metab Syndr Obes. 2018 Sep 25;11:533-542. doi: 10.2147/DMSO.S146339. eCollection 2018.
9
GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care.全科医生对早期发现肝病的经验和看法:初级保健中的定性研究。
Br J Gen Pract. 2018 Nov;68(676):e743-e749. doi: 10.3399/bjgp18X699377. Epub 2018 Sep 24.
10
Survey on knowledge of non-alcoholic fatty liver disease (NAFLD) among doctors in Sri Lanka: a multicenter study.斯里兰卡医生对非酒精性脂肪性肝病(NAFLD)的知识调查:一项多中心研究。
BMC Res Notes. 2018 Aug 3;11(1):556. doi: 10.1186/s13104-018-3673-2.